Overview

* Surrozen ( SRZN ) Q2 net income $39.7 mln, reversing loss from previous year

* Company advances ophthalmology pipeline with SZN-8141 and SZN-8143

* Cash position at $90.4 mln, down from previous quarter

Highlights in Q2

* OPHTHALMOLOGY PIPELINE - Progress on lead candidates SZN-8141 and SZN-8143 for retinal diseases

* Co notes it is on track to submit an Investigational New Drug (IND) application for SZN-8141 in 2026.

* PATENT ISSUANCE - U.S. Patent granted for SWAP™ technology, strengthening intellectual property for SZN-8141 and SZN-8143

* LEADERSHIP APPOINTMENT - Dr. Daniel Chao joins as VP of Clinical Development, bringing extensive expertise in ophthalmology

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS $2.55

Q2 Net $39.75

Income mln

Q2 $10 mln

Operatin

g

Expenses

Q2 -$9.02

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Surrozen Inc ( SRZN ) is $37.00, about 75.6% above its August 7 closing price of $9.03

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)